[SCHEDULE 13G/A] Lexeo Therapeutics, Inc. SEC Filing
This Schedule 13G/A reports the beneficial ownership positions of multiple Frazier Life Sciences entities in Lexeo Therapeutics, Inc. common stock and clarifies prior attributions. Frazier Life Sciences Public Fund, L.P. directly holds 3,073,467 shares and related entities hold additional positions including 624,804, 87,424, 232,784 and 406,246 shares across several affiliated funds, with individual percentages reported as high as 5.7% and others at 1.2%, 0.2%, 0.4% and 0.8% respectively.
The filing states these reported share amounts exclude certain warrants and discloses warrant ceilings: FLSPF holds warrants to purchase 2,647,440 shares; FLSPOF 781,005; FLS X 109,280; FLS XI 290,980; and FLS XII 507,809, each subject to a ~9.99% beneficial-ownership exercise limit. The statement explains shared voting and dispositive power structures through general partners and investment committees and corrects any prior over-attribution to individual committee members. The percentage calculations rely on the issuer's reported outstanding shares and shares sold in a public offering as set forth in the filing.
Questo Schedule 13G/A riporta le posizioni di propriet脿 beneficiaria di pi霉 entit脿 di Frazier Life Sciences nelle azioni ordinarie di Lexeo Therapeutics, Inc. e chiarisce precedenti attribuzioni. Frazier Life Sciences Public Fund, L.P. detiene direttamente 3,073,467 azioni e entit脿 correlate detengono posizioni aggiuntive comprensive di 624,804, 87,424, 232,784 e 406,246 azioni attraverso diversi fondi affiliati, con percentuali individuali riportate fino a 5.7% e altre pari a 1.2%, 0.2%, 0.4% e 0.8% rispettivamente.
Il deposito indica che questi importi di azioni riportati escludono determinati warrant e rende note le soglie dei warrant: FLSPF detiene warrant per l'acquisto di 2,647,440 azioni; FLSPOF 781,005; FLS X 109,280; FLS XI 290,980; e FLS XII 507,809, ciascuno soggetto a un limite di esercizio di circa ~9.99% della propriet脿 beneficiaria. La dichiarazione spiega le strutture di condivisione del potere di voto e di disposizione tramite i soci accomandatari e i comitati d'investimento e corregge eventuali precedenti sovra-attribuzioni ai singoli membri del comitato. I calcoli percentuali si basano sulle azioni in circolazione segnalate dall'emittente e sulle azioni vendute in un'offerta pubblica come indicato nel deposito.
Este Schedule 13G/A informa las posiciones de propiedad beneficiaria de varias entidades de Frazier Life Sciences en acciones ordinarias de Lexeo Therapeutics, Inc. y aclara atribuciones previas. Frazier Life Sciences Public Fund, L.P. posee directamente 3,073,467 acciones y entidades relacionadas mantienen posiciones adicionales por 624,804, 87,424, 232,784 y 406,246 acciones a trav茅s de varios fondos afiliados, con porcentajes individuales reportados de hasta 5.7% y otros de 1.2%, 0.2%, 0.4% y 0.8%, respectivamente.
La presentaci贸n indica que estas cantidades de acciones reportadas excluyen ciertos warrants y revela los techos de warrants: FLSPF posee warrants para comprar 2,647,440 acciones; FLSPOF 781,005; FLS X 109,280; FLS XI 290,980; y FLS XII 507,809, cada uno sujeto a un l铆mite de ejercicio de aproximadamente ~9.99% de propiedad beneficiaria. La declaraci贸n explica las estructuras compartidas de poder de voto y disposici贸n mediante los socios generales y comit茅s de inversi贸n y corrige cualquier atribuci贸n excesiva previa a miembros individuales del comit茅. Los c谩lculos porcentuales se basan en las acciones en circulaci贸n reportadas por el emisor y en las acciones vendidas en una oferta p煤blica seg煤n consta en la presentaci贸n.
氤� Schedule 13G/A電� Lexeo Therapeutics, Inc. 氤错喌欤检棎 雽�頃� 鞐煬 Frazier Life Sciences 瓿勳棿靷潣 鞁れ鞝� 靻岇湢歆�攵勳潉 氤搓碃頃橁碃 鞚挫爠鞚� 攴�靻� 靷暛鞚� 氇呿檿頌� 頃╇媹雼�. Frazier Life Sciences Public Fund, L.P.電� 歆侅爲鞝侅溂搿� 3,073,467欤�毳� 氤挫湢頃橁碃 鞛堨溂氅� 甏�霠� 旮瓣磤霌れ潃 鞐煬 瓿勳棿 韼�霌滊ゼ 韱淀暣 624,804, 87,424, 232,784 氚� 406,246欤检潣 於旉皜 韽靺橃潉 氤挫湢頃橁碃 鞛堦碃, 臧滊硠 牍勳湪鞚� 斓滊寑 5.7%, 攴� 氚栰棎 1.2%, 0.2%, 0.4% 氚� 0.8%搿� 氤搓碃霅橃柎 鞛堨姷雼堧嫟.
頃措嫻 鞝滌稖靹滊電� 氤搓碃霅� 鞚� 欤检嫕 靾橂焿鞚� 鞚茧秬 鞗岆煱韸鸽ゼ 鞝滌櫢頃滊嫟瓿� 氚濏瀳瓿� 鞗岆煱韸� 頃滊弰毳� 瓿奠嫓頃╇媹雼�: FLSPF電� 2,647,440欤茧ゼ 毵れ垬頃� 靾� 鞛堧姅 鞗岆煱韸鸽ゼ; FLSPOF電� 781,005; FLS X電� 109,280; FLS XI電� 290,980; FLS XII電� 507,809毳� 氤挫湢頃橁碃 鞛堨溂氅�, 臧侁皝 鞎� ~9.99%鞚� 鞁れ 靻岇湢甓� 頄夓偓 頃滊弰鞐� 霐半雼堧嫟. 氤� 氇呾劯靹滊姅 鞝滊剤霟� 韺岉姼雱堨檧 韴瀽鞙勳洂須岆ゼ 韱淀暅 鞚橁舶甓� 氚� 觳橂秳甓岇潣 瓿奠湢 甑“毳� 靹る獏頃橁碃 鞙勳洂須� 臧滊硠 甑劚鞗愳棎 雽�頃� 瓿茧弰頃� 鞚挫爠 攴�靻嶌潉 鞝曥爼頃╇媹雼�. 氚彪秳鞙� 瓿勳偘鞚� 鞝滌稖靹滊鞐� 旮办灛霅� 氚滍枆須岇偓鞚� 氤搓碃霅� 鞙犿喌 欤检嫕靾橃檧 瓿店皽 氇鞐愳劀 韺愲Г霅� 欤检嫕鞚� 旮办鞙茧 頃╇媹雼�.
Ce Schedule 13G/A rend compte des positions de propri茅t茅 b茅n茅ficiaire de plusieurs entit茅s Frazier Life Sciences sur les actions ordinaires de Lexeo Therapeutics, Inc. et clarifie des attributions ant茅rieures. Frazier Life Sciences Public Fund, L.P. d茅tient directement 3,073,467 actions et des entit茅s affili茅es d茅tiennent des positions additionnelles de 624,804, 87,424, 232,784 et 406,246 actions via plusieurs fonds affili茅s, avec des pourcentages individuels rapport茅s jusqu'脿 5.7% et d'autres 脿 1.2%, 0.2%, 0.4% et 0.8% respectivement.
Le d茅p么t pr茅cise que ces montants d'actions d茅clar茅s excluent certains bons de souscription (warrants) et divulgue les plafonds de warrants : FLSPF d茅tient des warrants pour acqu茅rir 2,647,440 actions ; FLSPOF 781,005 ; FLS X 109,280 ; FLS XI 290,980 ; et FLS XII 507,809, chacun soumis 脿 une limite d'exercice d'environ ~9.99% de propri茅t茅 b茅n茅ficiaire. La d茅claration explique les structures de partage du pouvoir de vote et du pouvoir de disposition via les commandit茅s et les comit茅s d'investissement et corrige toute attribution excessive ant茅rieure 脿 des membres individuels du comit茅. Les calculs en pourcentage reposent sur le nombre d'actions en circulation d茅clar茅 par l'茅metteur et sur les actions vendues dans une offre publique comme indiqu茅 dans le d茅p么t.
Dieses Schedule 13G/A meldet die wirtschaftlichen Eigentumspositionen mehrerer Frazier Life Sciences-Einheiten an Stammaktien der Lexeo Therapeutics, Inc. und stellt fr眉here Zuschreibungen klar. Frazier Life Sciences Public Fund, L.P. h盲lt direkt 3,073,467 Aktien und verbundene Gesellschaften halten zus盲tzliche Positionen in H枚he von 624,804, 87,424, 232,784 und 406,246 Aktien 眉ber mehrere angeschlossene Fonds, wobei einzelne Prozents盲tze mit bis zu 5.7% und weitere mit 1.2%, 0.2%, 0.4% und 0.8% angegeben werden.
Die Einreichung stellt fest, dass diese gemeldeten Aktienmengen bestimmte Warrants ausschlie脽en und offenbart die Warrant-Obergrenzen: FLSPF h盲lt Warrants zum Erwerb von 2,647,440 Aktien; FLSPOF 781,005; FLS X 109,280; FLS XI 290,980; und FLS XII 507,809, jeweils unterliegt jedes einem Aus眉bungsgrenzwert von rund ~9.99% des wirtschaftlichen Eigentums. Die Erkl盲rung erl盲utert die gemeinsamen Strukturen von Stimm- und Verf眉gungsgewalt 眉ber General Partner und Investmentkomitees und korrigiert etwaige fr眉here 脺berzuschreibungen auf einzelne Komiteemitglieder. Die Prozentberechnungen basieren auf den vom Emittenten gemeldeten ausstehenden Aktien und den in einem 枚ffentlichen Angebot verkauften Aktien, wie in der Einreichung dargestellt.
- Clarifies beneficial ownership of Lexeo Therapeutics shares and corrects prior over-attribution to individual committee members
- Discloses warrant holdings and exercise limits (e.g., FLSPF warrants for 2,647,440 shares), allowing clearer assessment of potential dilution
- None.
Insights
TL;DR: Clarifying a >5% stake and allocation of warrants reduces prior over-attribution and improves disclosure transparency.
The filing provides detailed, corrective disclosure on who holds voting and dispositive power across multiple affiliated Frazier funds. The confirmation that FLSPF directly holds 3,073,467 shares (reported as ~5.7%) is material for investor ownership tables. The explicit exclusion of warrants from reported share counts and the identification of warrant volumes and 9.99% exercise limits is important for modeling potential dilution. This is primarily an informational, transparency-driven update rather than a change in control.
TL;DR: The statement corrects attribution of ownership among investment-committee-managed entities, narrowing individual director/member holdings.
The filing explains governance arrangements: several general partners are managed by investment committees whose members are not being attributed beneficial ownership of fund holdings, and the filing expressly corrects prior attributions. That clarification reduces ambiguity about which individuals exercise voting power over the reported stakes. For governance analysis, the distinction between shared fund-level power and individual member ownership is material to assessing influence but does not indicate any new corporate governance action.
Questo Schedule 13G/A riporta le posizioni di propriet脿 beneficiaria di pi霉 entit脿 di Frazier Life Sciences nelle azioni ordinarie di Lexeo Therapeutics, Inc. e chiarisce precedenti attribuzioni. Frazier Life Sciences Public Fund, L.P. detiene direttamente 3,073,467 azioni e entit脿 correlate detengono posizioni aggiuntive comprensive di 624,804, 87,424, 232,784 e 406,246 azioni attraverso diversi fondi affiliati, con percentuali individuali riportate fino a 5.7% e altre pari a 1.2%, 0.2%, 0.4% e 0.8% rispettivamente.
Il deposito indica che questi importi di azioni riportati escludono determinati warrant e rende note le soglie dei warrant: FLSPF detiene warrant per l'acquisto di 2,647,440 azioni; FLSPOF 781,005; FLS X 109,280; FLS XI 290,980; e FLS XII 507,809, ciascuno soggetto a un limite di esercizio di circa ~9.99% della propriet脿 beneficiaria. La dichiarazione spiega le strutture di condivisione del potere di voto e di disposizione tramite i soci accomandatari e i comitati d'investimento e corregge eventuali precedenti sovra-attribuzioni ai singoli membri del comitato. I calcoli percentuali si basano sulle azioni in circolazione segnalate dall'emittente e sulle azioni vendute in un'offerta pubblica come indicato nel deposito.
Este Schedule 13G/A informa las posiciones de propiedad beneficiaria de varias entidades de Frazier Life Sciences en acciones ordinarias de Lexeo Therapeutics, Inc. y aclara atribuciones previas. Frazier Life Sciences Public Fund, L.P. posee directamente 3,073,467 acciones y entidades relacionadas mantienen posiciones adicionales por 624,804, 87,424, 232,784 y 406,246 acciones a trav茅s de varios fondos afiliados, con porcentajes individuales reportados de hasta 5.7% y otros de 1.2%, 0.2%, 0.4% y 0.8%, respectivamente.
La presentaci贸n indica que estas cantidades de acciones reportadas excluyen ciertos warrants y revela los techos de warrants: FLSPF posee warrants para comprar 2,647,440 acciones; FLSPOF 781,005; FLS X 109,280; FLS XI 290,980; y FLS XII 507,809, cada uno sujeto a un l铆mite de ejercicio de aproximadamente ~9.99% de propiedad beneficiaria. La declaraci贸n explica las estructuras compartidas de poder de voto y disposici贸n mediante los socios generales y comit茅s de inversi贸n y corrige cualquier atribuci贸n excesiva previa a miembros individuales del comit茅. Los c谩lculos porcentuales se basan en las acciones en circulaci贸n reportadas por el emisor y en las acciones vendidas en una oferta p煤blica seg煤n consta en la presentaci贸n.
氤� Schedule 13G/A電� Lexeo Therapeutics, Inc. 氤错喌欤检棎 雽�頃� 鞐煬 Frazier Life Sciences 瓿勳棿靷潣 鞁れ鞝� 靻岇湢歆�攵勳潉 氤搓碃頃橁碃 鞚挫爠鞚� 攴�靻� 靷暛鞚� 氇呿檿頌� 頃╇媹雼�. Frazier Life Sciences Public Fund, L.P.電� 歆侅爲鞝侅溂搿� 3,073,467欤�毳� 氤挫湢頃橁碃 鞛堨溂氅� 甏�霠� 旮瓣磤霌れ潃 鞐煬 瓿勳棿 韼�霌滊ゼ 韱淀暣 624,804, 87,424, 232,784 氚� 406,246欤检潣 於旉皜 韽靺橃潉 氤挫湢頃橁碃 鞛堦碃, 臧滊硠 牍勳湪鞚� 斓滊寑 5.7%, 攴� 氚栰棎 1.2%, 0.2%, 0.4% 氚� 0.8%搿� 氤搓碃霅橃柎 鞛堨姷雼堧嫟.
頃措嫻 鞝滌稖靹滊電� 氤搓碃霅� 鞚� 欤检嫕 靾橂焿鞚� 鞚茧秬 鞗岆煱韸鸽ゼ 鞝滌櫢頃滊嫟瓿� 氚濏瀳瓿� 鞗岆煱韸� 頃滊弰毳� 瓿奠嫓頃╇媹雼�: FLSPF電� 2,647,440欤茧ゼ 毵れ垬頃� 靾� 鞛堧姅 鞗岆煱韸鸽ゼ; FLSPOF電� 781,005; FLS X電� 109,280; FLS XI電� 290,980; FLS XII電� 507,809毳� 氤挫湢頃橁碃 鞛堨溂氅�, 臧侁皝 鞎� ~9.99%鞚� 鞁れ 靻岇湢甓� 頄夓偓 頃滊弰鞐� 霐半雼堧嫟. 氤� 氇呾劯靹滊姅 鞝滊剤霟� 韺岉姼雱堨檧 韴瀽鞙勳洂須岆ゼ 韱淀暅 鞚橁舶甓� 氚� 觳橂秳甓岇潣 瓿奠湢 甑“毳� 靹る獏頃橁碃 鞙勳洂須� 臧滊硠 甑劚鞗愳棎 雽�頃� 瓿茧弰頃� 鞚挫爠 攴�靻嶌潉 鞝曥爼頃╇媹雼�. 氚彪秳鞙� 瓿勳偘鞚� 鞝滌稖靹滊鞐� 旮办灛霅� 氚滍枆須岇偓鞚� 氤搓碃霅� 鞙犿喌 欤检嫕靾橃檧 瓿店皽 氇鞐愳劀 韺愲Г霅� 欤检嫕鞚� 旮办鞙茧 頃╇媹雼�.
Ce Schedule 13G/A rend compte des positions de propri茅t茅 b茅n茅ficiaire de plusieurs entit茅s Frazier Life Sciences sur les actions ordinaires de Lexeo Therapeutics, Inc. et clarifie des attributions ant茅rieures. Frazier Life Sciences Public Fund, L.P. d茅tient directement 3,073,467 actions et des entit茅s affili茅es d茅tiennent des positions additionnelles de 624,804, 87,424, 232,784 et 406,246 actions via plusieurs fonds affili茅s, avec des pourcentages individuels rapport茅s jusqu'脿 5.7% et d'autres 脿 1.2%, 0.2%, 0.4% et 0.8% respectivement.
Le d茅p么t pr茅cise que ces montants d'actions d茅clar茅s excluent certains bons de souscription (warrants) et divulgue les plafonds de warrants : FLSPF d茅tient des warrants pour acqu茅rir 2,647,440 actions ; FLSPOF 781,005 ; FLS X 109,280 ; FLS XI 290,980 ; et FLS XII 507,809, chacun soumis 脿 une limite d'exercice d'environ ~9.99% de propri茅t茅 b茅n茅ficiaire. La d茅claration explique les structures de partage du pouvoir de vote et du pouvoir de disposition via les commandit茅s et les comit茅s d'investissement et corrige toute attribution excessive ant茅rieure 脿 des membres individuels du comit茅. Les calculs en pourcentage reposent sur le nombre d'actions en circulation d茅clar茅 par l'茅metteur et sur les actions vendues dans une offre publique comme indiqu茅 dans le d茅p么t.
Dieses Schedule 13G/A meldet die wirtschaftlichen Eigentumspositionen mehrerer Frazier Life Sciences-Einheiten an Stammaktien der Lexeo Therapeutics, Inc. und stellt fr眉here Zuschreibungen klar. Frazier Life Sciences Public Fund, L.P. h盲lt direkt 3,073,467 Aktien und verbundene Gesellschaften halten zus盲tzliche Positionen in H枚he von 624,804, 87,424, 232,784 und 406,246 Aktien 眉ber mehrere angeschlossene Fonds, wobei einzelne Prozents盲tze mit bis zu 5.7% und weitere mit 1.2%, 0.2%, 0.4% und 0.8% angegeben werden.
Die Einreichung stellt fest, dass diese gemeldeten Aktienmengen bestimmte Warrants ausschlie脽en und offenbart die Warrant-Obergrenzen: FLSPF h盲lt Warrants zum Erwerb von 2,647,440 Aktien; FLSPOF 781,005; FLS X 109,280; FLS XI 290,980; und FLS XII 507,809, jeweils unterliegt jedes einem Aus眉bungsgrenzwert von rund ~9.99% des wirtschaftlichen Eigentums. Die Erkl盲rung erl盲utert die gemeinsamen Strukturen von Stimm- und Verf眉gungsgewalt 眉ber General Partner und Investmentkomitees und korrigiert etwaige fr眉here 脺berzuschreibungen auf einzelne Komiteemitglieder. Die Prozentberechnungen basieren auf den vom Emittenten gemeldeten ausstehenden Aktien und den in einem 枚ffentlichen Angebot verkauften Aktien, wie in der Einreichung dargestellt.
FAQ
What stake in Lexeo Therapeutics (LXEO) does Frazier Life Sciences Public Fund, L.P. report?
Do the reported share totals include warrants for LXEO?
How were the ownership percentages calculated in the filing for LXEO?
Which Frazier entities report shared voting or dispositive power over LXEO shares?
Does the filing change who is attributed ownership among investment-committee-managed entities?
